Medicine and Dentistry

Queen Mary-led digital listening test to be trialled across NHS to help improve dementia diagnosis

A new digital test developed by researchers at Queen Mary University of London could help people receive a faster and more accurate diagnosis of dementia, as part of a major new UK-wide initiative.

Robotic hip and knee surgery fails to cut overall risk of repeat surgery

Two major studies involving researchers at Queen Mary University of London have found that robotic-assisted hip and knee replacement does not reduce the overall early risk of repeat surgery compared with conventional surgery.

Non-invasive nerve stimulation shows potential for treating uncontrolled high blood pressure

A non-invasive technique that stimulates nerves through the ear has been shown to be safe, well tolerated and easy for patients with uncontrolled high blood pressure to use at home, according to a clinical trial led by researchers at Queen Mary University of London.

Queen Mary scientists overcome key barrier to self-amplifying vaccines

The innovation could enable protection at lower doses, meaning vaccines could be rolled out further and faster than was previously imaginable, and opens new possibilities in gene therapy, cancer immunotherapy, and protein replacement therapies.

Major NHS trial provides new evidence on multi-cancer blood test

Results from the world’s first randomised controlled trial of a multi-cancer early detection blood test have been published in two leading medical journals, providing important new evidence on whether the test can change how cancers are diagnosed and how it performs when used for population screening.

Patient’s immune system could help predict success of CAR-T cell therapy

Researchers, including scientists at Queen Mary University of London, have identified biological factors that could help predict whether patients will respond successfully to CAR-T cell therapy when lower numbers of therapeutic cells are available.

Queen Mary research behind potential new heart attack treatment shows promise in Phase 2 trial

Research originating at Queen Mary University of London’s William Harvey Research Institute (WHRI) has helped underpin a potential new treatment designed to protect the heart from inflammation-related damage following a severe heart attack.

Blood protein analysis could help diagnose rare diseases missed by genome sequencing

Combining information about proteins in the blood with genomic data provides new answers for some people with rare diseases who previously remained undiagnosed after genome sequencing, research suggests.

Queen Mary joins £10m international programme to tackle drug-resistant tuberculosis

New international research programme will bring together researchers and national tuberculosis programmes across five high-burden countries to better understand emerging drug resistance and improve treatment.

Where body fat is stored may matter more than BMI for heart health

A study led by researchers at Queen Mary University of London has found that where fat is stored in the body may be a better indicator of heart health than body mass index (BMI) alone.

Blog: When AI meets Phage Display: Accelerating the future for life-saving antibodies

Ahuva Nissim is Professor in antibody and Therapeutic Engineering at Queen Mary University of London. In this article, Professor Nissim explore the potential of AI-designed artificial phage and how they could help address antibiotic resistance while opening new avenues for drug discovery.

Introduction of London’s Ultra Low Emission Zone linked to improved lung growth in children

A landmark study of more than 3,400 children, led by Queen Mary University of London, has found that air quality improvements following the introduction of London’s Ultra Low Emission Zone (ULEZ) are strongly associated with accelerated lung growth in children.

International study shows once-weekly HIV pill performs as well as daily treatment

An international clinical trial led by researchers including Professor Chloe Orkin of Queen Mary University of London has shown that a once-weekly oral treatment for HIV is as effective as one of today’s leading daily therapies, offering the potential for a new treatment option that could reduce the burden of lifelong daily pill-taking. 

New Nature Genetics study unlocks fresh insights into disease biology and future drug discovery

Research led by scientists at Queen Mary University of London has shown how next-generation blood protein analysis can uncover important biological insights that conventional technologies miss, opening up new opportunities to better understand disease and identify future drug targets.

AI combines multiple DNA clues to improve cancer detection from blood

Researchers have developed an artificial intelligence method that can detect signs of cancer by combining several different clues found in DNA fragments circulating in the blood.

Blog: How England is weighing the cost of genomic newborn screening

New research led by Queen Mary University of London assesses the cost of genomic screening for newborns in England. 

Major step forward as new approach to rare disease drug development yields first research results.

The TREAT-EB collaboration between Queen Mary University of London and DEBRA Research aims to circumvent the discovery bottleneck blocking treatments for epidermolysis bullosa.

New brush test detects oral cancer in one hour

A paper published in the Nature journal Biomarker Research by a cross-University team led by Queen Mary University of London researchers, validates the use of a non-invasive brush biopsy test that can detect oral cancer within one hour. 

Hip fracture patients three times less likely to need repeat surgery with dual mobility hip replacements

A major international clinical trial led by Queen Mary University of London and Uppsala University in Sweden has found that an emerging type of hip replacement implant dramatically reduces complications in people with a broken hip.

Cervical cancer deaths plummet to record low thanks to HPV vaccine

First of its kind research, led by Queen Mary University of London and funded by Cancer Research UK, shows that the human papillomavirus (HPV) vaccine is reducing cervical cancer deaths in England.

New theory over mystery death of Botticelli’s Birth of Venus model, Simonetta Vespucci

Expansion of pituitary adenoma may have caused her premature death at 23, and be the cause of her long-admired Strabismus (squint) of Venus 

New AI heart failure screening tool could save lives, cut hospital waiting lists and deliver major NHS cost savings

Scientists at Queen Mary University of London and Barts Health NHS Trust have been awarded £1.3m to develop the invention for use in the NHS.

New funding allows TRANSFORM prostate cancer research trial to invite all eligible black men

The UK Department of Health and Social Care has announced an additional investment of up to £18m, to extend the landmark TRANSFORM prostate cancer screening trial to invite all eligible Black men aged 45-74 who have not had a recent PSA blood test to participate.

Queen Mary biologist Dr Suzanne Eldridge shortlisted for top business award.

The nomination signals the growing importance of high-value science-led innovation within British entrepreneurship.

First results from NHS-Galleri trial presented at international conference

Today (Saturday 30th May 2026), the first full results from the NHS-Galleri trial, a research study looking into the use of a blood test to see if it can help the NHS to detect cancer early, have been presented at the annual American Society for Clinical Oncology conference.

Drug slows progression of MS

Trial results show that ocrelizumab helps preserve hand function and reduce the risk of wheelchair dependence in people with primary progressive multiple sclerosis (MS).

Queen Mary academics elected Fellows of the Academy of Medical Sciences

Two Professors from Queen Mary University of London have been selected for the 2026 Fellowship of the Academy of Medical Sciences. The honour recognises individuals who have demonstrated exceptional leadership and achievement in advancing medical science, improving healthcare and delivering benefits to patients and communities. 

Largest study on genetics of blood proteins uncovers new disease mechanisms and drug repurposing opportunities

Involving a collaboration with 118 investigators contributing from 89 institutions, scientists from Queen Mary University of London’s Precision Healthcare University Research Institute and Berlin Institute of Health (BIH) at Charité have led the world’s largest study on the genetic regulation of blood proteins.

Scientists discover how HIV hijacks a cellular 'gateway' to infect resting immune cells

The findings, produced by researchers from Queen Mary University of London and published in Nature, overturn long-held assumptions about HIV infection and could reshape understanding of how the virus establishes hidden reservoirs in the body. 

Professor Claudia Langenberg elected as member of Germany’s Leopoldina

Professor Claudia Langenberg, Director of Queen Mary’s Precision Healthcare Research University Research Institute (PHURI) has been elected to the prestigious German National Academy of Medical Sciences, the Leopoldina.